Workflow
方达控股(01521) - 2024 - 中期业绩
01521FRONTAGE(01521)2024-08-28 10:30

Financial Performance - Revenue for the six months ended June 30, 2024, was 128.5million,aslightincreaseof0.1128.5 million, a slight increase of 0.1% compared to 128.4 million in the same period of 2023[2] - Gross profit decreased to 34.8millionwithagrossmarginof27.134.8 million with a gross margin of 27.1%, down from 39.0 million and 30.4% in the prior year, representing a decline of 10.8%[2] - Adjusted EBITDA for the period was 25.8million,withanadjustedEBITDAmarginof20.125.8 million, with an adjusted EBITDA margin of 20.1%, down from 29.8 million and 23.2% in the previous year, a decrease of 13.4%[2] - The company reported a net loss of 0.3million,translatingtoanetlossmarginof0.20.3 million, translating to a net loss margin of 0.2%, compared to a net profit of 4.6 million and a margin of 3.6% in the same period last year[2] - Adjusted net profit was 6.1million,withanadjustednetprofitmarginof4.86.1 million, with an adjusted net profit margin of 4.8%, down 40.2% from 10.2 million and 8.0% in the prior year[2] - Total comprehensive loss for the period was 2.973million,comparedtoacomprehensiveincomeof2.973 million, compared to a comprehensive income of 1.219 million in the same period of 2023[4] Assets and Liabilities - Non-current assets as of June 30, 2024, totaled 421.8million,adecreasefrom421.8 million, a decrease from 430.3 million as of December 31, 2023[6] - Current liabilities increased to 115.3millionfrom115.3 million from 99.6 million in the previous period, indicating a rise in short-term financial obligations[6] - Cash and cash equivalents decreased to 43.0millionfrom43.0 million from 53.2 million, reflecting a reduction in liquidity[6] - Non-current liabilities decreased from 127,142,000asofDecember31,2023,to127,142,000 as of December 31, 2023, to 116,279,000 as of June 30, 2024, a reduction of approximately 8.5%[7] - Net asset value decreased from 345,147,000to345,147,000 to 337,397,000, reflecting a decline of about 2.2%[7] Operational Changes - The company has restructured its operations into two main divisions: Global Laboratory Services and Global Drug Discovery and Development Services, aimed at improving efficiency[12] - The company operates primarily in North America, Europe, and China, with all consolidated assets and liabilities located in these regions[14] - The company has not presented segment assets and liabilities as they are not regularly provided to the chief operating decision maker for performance evaluation[14] Revenue Breakdown - Revenue breakdown includes laboratory testing services at 66,255,000,drugdevelopmentat66,255,000, drug development at 42,797,000, drug discovery at 15,820,000,andpharmaceuticalproductdevelopmentat15,820,000, and pharmaceutical product development at 3,603,000[13] - Revenue from laboratory testing in North America and Europe was 45,500,000,whileinChinaitwas45,500,000, while in China it was 12,993,000, totaling 58,493,000forthissegment[16]−RevenuefromNorthAmericaandEuropedecreasedby0.658,493,000 for this segment[16] - Revenue from North America and Europe decreased by 0.6% from approximately 100.0 million to approximately 99.4millionduringthesameperiod[56]−RevenuefromChinaincreasedby4.499.4 million during the same period[56] - Revenue from China increased by 4.4% from approximately RMB 197.8 million (approximately 28.4 million) to approximately RMB 206.5 million (approximately 29.1million)[56]Expenses−Researchanddevelopmentexpensesamountedto29.1 million)[56] Expenses - Research and development expenses amounted to 22,877,000 for the six months ended June 30, 2024, compared to 24,507,000inthesameperiodof2023,indicatingadecreaseof6.624,507,000 in the same period of 2023, indicating a decrease of 6.6%[16] - Sales and marketing expenses increased by 17.5% from approximately 4.0 million to approximately 4.7millionduetoenhancedmarketingandbusinessdevelopmentefforts[63]−Administrativeexpensesroseby7.04.7 million due to enhanced marketing and business development efforts[63] - Administrative expenses rose by 7.0% from approximately 22.9 million to approximately 24.5million,primarilyduetotheintegrationofNucroandFrontageEuropeintothegroup′sfinancialstatements[64]−Financialcostsincreasedby38.724.5 million, primarily due to the integration of Nucro and Frontage Europe into the group's financial statements[64] - Financial costs increased by 38.7% from approximately 3.1 million to approximately 4.3millionduetoincreasedborrowingsforexpansionandoperations[66]CashFlowandFinancing−Thegrouprecordedanetcashoutflowfromoperatingactivitiesof4.3 million due to increased borrowings for expansion and operations[66] Cash Flow and Financing - The group recorded a net cash outflow from operating activities of 4.6 million for the six months ended June 30, 2024, compared to 11.4millionforthesameperiodin2023[76]−CapitalexpendituresforthesixmonthsendedJune30,2024,wereapproximately11.4 million for the same period in 2023[76] - Capital expenditures for the six months ended June 30, 2024, were approximately 16.4 million, an increase of 42.6% from approximately 11.5millionforthesameperiodin2023,mainlyduetoincreasedspendingonNorthAmericanfacilities[77]−AsofJune30,2024,totalbankborrowingsamountedto11.5 million for the same period in 2023, mainly due to increased spending on North American facilities[77] - As of June 30, 2024, total bank borrowings amounted to 95.5 million, up from 81.4milliononDecember31,2023,withactualinterestratesrangingfrom2.7581.4 million on December 31, 2023, with actual interest rates ranging from 2.75% to 7.42%[78] Strategic Initiatives - The company completed the acquisition of Accelera S.r.l. for a cash consideration of €6,835,000 (approximately 7,357,000), with goodwill recognized at 6,275,000[42]−TheacquisitionofAcceleraisexpectedtoenhancethecompany′scapabilitiesinbioanalysisanddrugmetabolismservices,withafocusonexpandingscientificexpertiseandfacilities[45]−ThecompanylaunchedacommercialdiagnosticserviceforAlzheimer′sdisease,focusingonadvanceddiagnostictestingmethodstomeetthegrowingdemandforearlyandaccuratediagnosis[49]−Thecompanyplanstolaunchahigh−standardeyedropproductionlinebytheendof2024,expandingitsserviceofferingsandenhancingcompetitiveadvantage[54]MarketTrendsandChallenges−Thecontractresearchorganizationmarketisprojectedtogrowfromanestimatedvalueof6,275,000[42] - The acquisition of Accelera is expected to enhance the company's capabilities in bioanalysis and drug metabolism services, with a focus on expanding scientific expertise and facilities[45] - The company launched a commercial diagnostic service for Alzheimer's disease, focusing on advanced diagnostic testing methods to meet the growing demand for early and accurate diagnosis[49] - The company plans to launch a high-standard eye drop production line by the end of 2024, expanding its service offerings and enhancing competitive advantage[54] Market Trends and Challenges - The contract research organization market is projected to grow from an estimated value of 48.19 billion to $148.76 billion by 2028, driven by advancements in pharmaceutical and medical device R&D[47] - The company is addressing challenges in the contract research organization market, including high clinical trial costs and increased regulatory complexity, by optimizing cost structures and promoting technological innovation[47] - In 2024, the global and Chinese biopharmaceutical industry continues to experience cyclical downturns, with overall growth remaining slow despite signs of increased financing for biopharmaceutical companies[51] Governance and Compliance - The company's financial statements are prepared in accordance with International Financial Reporting Standards, ensuring compliance with applicable disclosure requirements[9] - The board confirmed compliance with the standard code of conduct for securities transactions by all directors during the reporting period[89] - The audit and risk management committee reviewed the interim performance and confirmed that the financial statements fairly reflect the group's financial position[91]